76338-90-4

Usage

Uses

Used in Pharmaceutical Industry:
(+/-)-2-AMINO-4-BROMOBUTANOIC ACID HBR is used as a starting material for the synthesis of antiepileptic drugs, contributing to the development of medications that help manage epilepsy and related conditions.
Used in Organic Chemistry:
(+/-)-2-AMINO-4-BROMOBUTANOIC ACID HBR is also utilized in the production of various other organic compounds, playing a crucial role in the synthesis of different chemical entities for research and industrial applications.
Safety Precautions:
This chemical is classified as a hazardous substance and should be handled with care to avoid skin and eye irritation. It is essential to store (+/-)-2-AMINO-4-BROMOBUTANOIC ACID HBR in a cool, dry place away from sources of ignition to ensure safety during its use and storage.

InChI:InChI=1/C4H8BrNO2.BrH/c5-2-1-3(6)4(7)8;/h3H,1-2,6H2,(H,7,8);1H

Upstream product

• 13602-48-7 3-benzoylamino-dihydro-furan-2-one 
• 6305-38-0 α-amino-γ-butyrolactone hydrobromide 

Downstream Products

• 58611-63-5 α-Amino-γ-brombuttersaeure-benzylester 
• 100606-81-3 2-amino-4-chloro-butyric acid methyl ester; hydrochloride 
• 76338-91-5 2-<(benzyloxycarbonyl)amino>-4-bromobutanoic acid methyl ester 
• 1927-25-9 DL-Homoserine 
• 2835-81-6 2-aminobutanoic acid 

Relevant academic research and scientific papers

DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-α]IMIDAZOLE-3- CARBOXYLIC ACID AMIDES

Derivatives of 6,7-dihydro-5H-imidazo[1,2-α]imidazole-3-carboxylic acid amide exhibit good inhibitory effect upon the interaction of CAMs and Leukointegrins and are thus useful in the treatment of inflammatory disease.

2-SULFONYLAMINO-4-HETEROARYL BUTYRAMIDE ANTAGONISTS OF CCR10

This invention relates to a compound of formula (I) and the pharmaceutically acceptable salts thereof wherein R1, R2, R4. Ar and Het are as defined herein. The invention also relates to methods of using the compound of for

ALPHA-SUBSTITUTED N-SULFONYL GYLCINE AMIDES ANTAGONISTS OF CCR10, COMPOSITIONS CONTAINING THE SAME AND METHODS FOR USING THEM

Disclosed is a compound of formula (I). Wherein R1, R2 Ar and Cy are as defined herein, or a pharmaceutically acceptable salt thereof. Also disclosed are pharmaceutical compositions of the compound of formula (I), methods of making t

S-alkylated homocysteine derivatives: New inhibitors of human betaine-homocysteine S-methyltransferase

A series of S-alkylated derivatives of homocysteine were synthesized and characterized as inhibitors of human recombinant betaine-homocysteine S-methyltransferase (BHMT). Some of these compounds inhibit BHMT with IC 50 values in the nanomolar r

Cyclic hydroxamates, especially multiply substituted [1,2]oxazinan-3-ones

Routes to putative N-acyl-D-ala-D-ala surrogates, beginning with the conversion of 4-, 5-, and 6-membered lactones into 5-, 6-, and 7-membered cyclic hydroxamates, are reported. The key step of the synthesis is trimethylaluminium-promoted cyclization of an ω-aminooxyester. The 7-membered cyclic hydroxamate crystallizes in a chair conformation. Extension of the reaction sequence to homoserine or homoserine lactone leads to cyclocanaline and N-acylated cyclocanalines. The 4-phenylacetamido derivative of cyclocanaline crystallizes in a boat conformation. The attachment of a 2-carboxypropyl substituent to the ring nitrogen of a 4-acylaminocyclocanaline has been effected, prior to cyclization, by coupling of the acyclic aminooxyester precursor to the triflate of benzyl lactate or, after cyclization, by coupling to tert-butyl α-bromopropionate in the presence of potassium fluoride - alumina, followed by removal of the protecting group in each case. A six-membered homolog of the antibiotic lactivicin has been synthesized by the reaction of 4-phenylacetamidocyclocanaline with benzyl 2-oxoglutarate in the presence of carbodiimide, followed by hydrogenolysis. Starting with methyl 2,4-dibromo-2,4-dideoxy-L-erythronate, which is available in two steps from L-ascorbic acid, these reaction sequences have been applied to the stereospecific synthesis of a D-alanine derivative whose nitrogen atom is enclosed within a 3,4-disubstituted [1,2]oxazinan-3-one.

Design and synthesis of phosphonate inhibitors of glutamine synthetase

Inhibitors 1-4 have been shown previously to undergo enzymatic phosphorylation by glutamine synthetase (GS). Phosphonates 6-9 were designed as chemically stable analogues of these phosphorylated inhibitors, incorporating either a tetrahedral sulfur group

Comestibles sweetened with alpha amino acid dihydrochalcones

Dihydrochalcones of the formula STR1 are disclosed wherein X is H or OH and R is a lower alkyl. These materials are useful as sweeteners for edibles. A process for preparing these compounds using a novel intermediate is disclosed as are acid and base neutralization products of the subject dihydrochalcones.

Flavonone precursors for alpha amino acid dihydrochalcones

Dihydrochalcones of the formula STR1 are disclosed wherein X is H or OH and R is a lower alkyl. These materials are useful as sweeteners for edibles. A process for preparing these compounds using a novel intermediate is disclosed as are acid and base neutralization products of the subject dihydrochalcones.

Alpha amino acid dihydrochalcones

Dihydrochalcones of the formula STR1 are disclosed wherein X is H or OH and R is lower alkyl. These materials are useful as sweeteners for edibles. A process for preparing these compounds using a novel intermediate is disclosed as are acid and base neutralization products of the subject dihydrochalcones.